Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Shares Outstanding (Weighted Average): 2010-2025

Historic Shares Outstanding (Weighted Average) for Altimmune (ALT) over the last 16 years, with Sep 2025 value amounting to $88.3 million.

  • Altimmune's Shares Outstanding (Weighted Average) rose 24.18% to $88.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.3 million, marking a year-over-year increase of 24.18%. This contributed to the annual value of $71.1 million for FY2024, which is 32.38% up from last year.
  • Altimmune's Shares Outstanding (Weighted Average) amounted to $88.3 million in Q3 2025, which was up 8.82% from $81.1 million recorded in Q2 2025.
  • Altimmune's 5-year Shares Outstanding (Weighted Average) high stood at $88.3 million for Q3 2025, and its period low was $37.2 million during Q1 2021.
  • In the last 3 years, Altimmune's Shares Outstanding (Weighted Average) had a median value of $70.9 million in 2024 and averaged $66.9 million.
  • Data for Altimmune's Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 147.29% (in 2021) over the last 5 years.
  • Over the past 5 years, Altimmune's Shares Outstanding (Weighted Average) (Quarterly) stood at $43.2 million in 2021, then climbed by 13.73% to $49.2 million in 2022, then grew by 9.30% to $53.7 million in 2023, then surged by 32.38% to $71.1 million in 2024, then increased by 24.18% to $88.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $88.3 million for Q3 2025, versus $81.1 million for Q2 2025 and $77.0 million for Q1 2025.